Introduction: Oncology treatment is characterized by complex therapeutic regimens, often involving medications with a narrow therapeutic margin, high toxicity, and a high risk of drug interactions, which increases the likelihood of medication errors and adverse events and requires specialized attention throughout patient care. Objectives: To describe and analyze the pharmaceutical interventions performed in an outpatient oncology pharmacy during the technical analysis of medical prescriptions, highlighting their nature, frequency, acceptance by the medical team, and associated clinical impact. Methods: This observational, descriptive, and retrospective study analyzed data recorded in an institutional spreadsheet of the outpatient oncology pharmacy of a High-Complexity Oncology Unit (UNACON) between January 2024 and April 2025. All pharmaceutical interventions performed by oncology clinical pharmacists during the technical analysis of outpatient prescriptions were included. Variables assessed comprised the type of intervention, the reason for intervention, and the outcome regarding acceptance by the medical team. Data were organized in Microsoft Excel® spreadsheets and analyzed using descriptive statistics, with results presented as absolute and relative frequencies. Results: A total of 4,788 pharmaceutical interventions were recorded during the study period. The most frequent interventions included adjustment of drug concentration in large-volume parenteral solutions (37%), supplementation or correction of patient data in prescriptions (28%), and adjustment of prescribed infusion time (25%). All interventions were accepted by the medical teams, corresponding to an acceptance rate of 100%. Antineoplastic agents and antiemetics were the most commonly involved drug classes. Additionally, 37% of the interventions directly contributed to the prevention of medication errors with potential clinical impact. Conclusion: Pharmaceutical interventions in the outpatient oncology setting play a strategic role in improving patient safety, reducing therapy-related risks, and optimizing clinical outcomes, reinforcing the importance of clinical pharmacy practice and systematic documentation of these actions in oncology care.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
